19,928 Shares in Qiagen (NYSE:QGEN) Bought by Beverly Hills Private Wealth LLC

Beverly Hills Private Wealth LLC purchased a new position in shares of Qiagen (NYSE:QGEN) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 19,928 shares of the company’s stock, valued at approximately $909,000.

Several other institutional investors have also modified their holdings of QGEN. Park Place Capital Corp purchased a new stake in shares of Qiagen during the second quarter valued at $31,000. WealthPLAN Partners LLC purchased a new stake in shares of Qiagen during the 1st quarter worth about $33,000. Altshuler Shaham Ltd purchased a new stake in shares of Qiagen during the 2nd quarter worth about $37,000. Assetmark Inc. raised its stake in shares of Qiagen by 41.6% in the 1st quarter. Assetmark Inc. now owns 834 shares of the company’s stock valued at $38,000 after acquiring an additional 245 shares in the last quarter. Finally, Captrust Financial Advisors raised its stake in shares of Qiagen by 23.1% in the 1st quarter. Captrust Financial Advisors now owns 1,232 shares of the company’s stock valued at $60,000 after acquiring an additional 231 shares in the last quarter. Institutional investors and hedge funds own 57.99% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on QGEN. HSBC lowered their target price on Qiagen from $64.00 to $57.00 in a report on Friday, September 29th. JPMorgan Chase & Co. decreased their price target on Qiagen from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 17th. TheStreet downgraded Qiagen from a “b-” rating to a “c+” rating in a research report on Thursday, September 14th. UBS Group dropped their target price on Qiagen from $48.00 to $42.00 and set a “neutral” rating for the company in a research report on Thursday, November 2nd. Finally, Citigroup restated a “buy” rating and set a $60.00 target price on shares of Qiagen in a research report on Tuesday, September 26th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $51.80.

Qiagen Price Performance

NYSE:QGEN opened at $39.54 on Wednesday. The company has a quick ratio of 2.98, a current ratio of 3.74 and a debt-to-equity ratio of 0.37. The stock’s 50 day moving average price is $39.34 and its two-hundred day moving average price is $43.25. The firm has a market capitalization of $9.02 billion, a price-to-earnings ratio of 27.27, a P/E/G ratio of 11.37 and a beta of 0.40. Qiagen has a 12-month low of $34.74 and a 12-month high of $51.18.

Qiagen (NYSE:QGEN) last announced its earnings results on Monday, October 30th. The company reported $0.50 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.01. The company had revenue of $476.00 million for the quarter, compared to analyst estimates of $469.79 million. Qiagen had a return on equity of 13.15% and a net margin of 17.01%. The firm’s quarterly revenue was down 4.8% compared to the same quarter last year. During the same quarter last year, the company earned $0.53 earnings per share. On average, analysts anticipate that Qiagen will post 2.06 earnings per share for the current year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.